Results 361 to 370 of about 510,342 (390)

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma

Journal of Clinical Oncology, 2022
Luciano J Costa, Saurabh Chhabra, Eva Medvedova   +2 more
exaly  

The nuclear export protein XPO1 — from biology to targeted therapy

Nature Reviews Clinical Oncology, 2020
Asfar S Azmi, Mohammed H Uddin, Ramzi M Mohammad   +2 more
exaly  

Dexamethasone in Ophthalmology

American Journal of Ophthalmology, 1959
openaire   +2 more sources

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Lancet, The, 2020
Sebastian Grosicki, Ivan Spicka, Maria Gavriatopoulou   +2 more
exaly  

Dexamethasone see Prednisone/dexamethasone

Reactions Weekly, 1990
openaire   +1 more source

Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy

Nature Medicine, 2007
Ursula Grohmann, Claudia Volpi, Francesca Fallarino   +2 more
exaly  

Dexamethasone

Reactions Weekly, 2012
openaire   +2 more sources

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Lancet, The, 2019
Phillipe Moreau, Michel M Attal, `Cyrille Hulin   +2 more
exaly  

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

Lancet Oncology, The, 2020
Shaji K Kumar, Simon J Harrison, Michele Cavo   +2 more
exaly  

Dexamethasone see Vincristine/dexamethasone

Reactions Weekly, 1991
openaire   +1 more source